24534-93-8

Basic information

• Product Name: 3-HYDROXYBUTANOHYDRAZIDE
• Synonyms: 3-HYDROXYBUTANOHYDRAZIDE;3-hydroxybutanohydrazide(SALTDATA: FREE);3-hydroxybutyrohydrazide
• CAS NO: 24534-93-8
• Molecular Formula: C₄H₁₀N₂O₂
• Molecular Weight: 118.14
• Mol File: 24534-93-8.mol
• Article Data: 4

Chemical Properties

• Melting Point: 126-128 °C
• Boiling Point: 345.5°Cat760mmHg
• Flash Point: 162.8°C
• Appearance: /
• Density: 1.157g/cm³
• Vapor Pressure: 3.85E-06mmHg at 25°C
• Refractive Index: 1.484
• PKA: 13.16±0.18(Predicted)
• CAS DataBase Reference: 3-HYDROXYBUTANOHYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-HYDROXYBUTANOHYDRAZIDE(24534-93-8)
• EPA Substance Registry System: 3-HYDROXYBUTANOHYDRAZIDE(24534-93-8)

Safety Data

• Hazardous Substances Data: 24534-93-8(Hazardous Substances Data)

Usage

General Description

3-HYDROXYBUTANOHYDRAZIDE, also known as isoniazid, is a medication used to treat tuberculosis. It works by inhibiting the growth of the bacteria that causes the disease. The chemical is a hydrazide derivative and is a prodrug, meaning it is converted into its active form in the body. 3-HYDROXYBUTANOHYDRAZIDE is typically taken orally and is well-absorbed in the gastrointestinal tract. It has a strong effect on the bacteria that causes tuberculosis and is an important component of tuberculosis treatment regimens. However, it may also have adverse effects such as hepatotoxicity and peripheral neuropathy, and it can interact with other medications, making it important for patients to be closely monitored during treatment.

InChI:InChI=1/C4H10N2O2/c1-3(7)2-4(8)6-5/h3,7H,2,5H2,1H3,(H,6,8)

Upstream product

• 3068-88-0 4-methyloxetan-2-one 
• 5405-41-4 ethyl 3-hydroxybutyrate 
• 1487-49-6 3-hydroxybutyric acid methyl ester 

Downstream Products

• 678555-15-2 3-Hydroxy-butyric acid [1-(2-chloro-phenyl)-meth-(E)-ylidene]-hydrazide 
• 133661-87-7 3-Hydroxy-butyric acid [1-(2-chloro-phenyl)-eth-(E)-ylidene]-hydrazide 

Relevant articles and documents

Discovery of a flexible triazolylbutanoic acid as a highly potent uric acid transporter 1 (URAT1) inhibitor

In order to systematically explore and understand the structure-activity relationship (SAR) of a lesinurad-based hit (1c) derived from the replacement of the S atom in lesinurad with CH2, 18 compounds (1a-1r) were designed, synthesized and subjected to in vitro URAT1 inhibitory assay. The SAR exploration led to the discovery of a highly potent flexible URAT1 inhibitor, 1q, which was 31-fold more potent than parent lesinurad (IC50 = 0.23 μM against human URAT1 for 1q vs. 7.18 μM for lesinurad). The present study discovered a flexible molecular scaffold, as represented by 1q, which might serve as a promising prototype scaffold for further development of potent URAT1 inhibitors, and also demonstrated that the S atom in lesinurad was not indispensable for its URAT1 inhibitory activity.

HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES

Disclosed are compounds of Formula Gl (structurally represented): where "RG3" "Rd1" to "Rd4", "n", "m", "p", "W", "X", "Y", and "Z" are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.